- Home
- IRON vs VBTX Comparison
IRON vs VBTX Comparison
Compare IRON & VBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- VBTX
- Stock Information
- Founded
- IRON 2017
- VBTX 2009
- Country
- IRON United States
- VBTX United States
- Employees
- IRON N/A
- VBTX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- VBTX Major Banks
- Sector
- IRON Health Care
- VBTX Finance
- Exchange
- IRON Nasdaq
- VBTX Nasdaq
- Market Cap
- IRON 1.4B
- VBTX 1.3B
- IPO Year
- IRON N/A
- VBTX 2014
- Fundamental
- Price
- IRON $46.68
- VBTX $24.20
- Analyst Decision
- IRON Strong Buy
- VBTX Buy
- Analyst Count
- IRON 9
- VBTX 6
- Target Price
- IRON $93.89
- VBTX $30.00
- AVG Volume (30 Days)
- IRON 354.8K
- VBTX 337.4K
- Earning Date
- IRON 05-07-2025
- VBTX 07-22-2025
- Dividend Yield
- IRON N/A
- VBTX 3.64%
- EPS Growth
- IRON N/A
- VBTX 18.60
- EPS
- IRON N/A
- VBTX 2.04
- Revenue
- IRON N/A
- VBTX $416,460,000.00
- Revenue This Year
- IRON N/A
- VBTX $12.52
- Revenue Next Year
- IRON N/A
- VBTX $5.50
- P/E Ratio
- IRON N/A
- VBTX $11.86
- Revenue Growth
- IRON N/A
- VBTX 14.03
- 52 Week Low
- IRON $30.82
- VBTX $19.27
- 52 Week High
- IRON $68.73
- VBTX $31.62
- Technical
- Relative Strength Index (RSI)
- IRON 49.90
- VBTX 51.10
- Support Level
- IRON $44.85
- VBTX $24.08
- Resistance Level
- IRON $47.36
- VBTX $24.74
- Average True Range (ATR)
- IRON 2.23
- VBTX 0.58
- MACD
- IRON -0.12
- VBTX -0.07
- Stochastic Oscillator
- IRON 37.58
- VBTX 35.88
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About VBTX Veritex Holdings Inc.
Veritex Holdings Inc is engaged in the provision of commercial banking products and services to small to medium-sized businesses and professionals. The bank provides a range of banking services to individual and corporate customers, which include commercial and retail lending, and the acceptance of checking and savings deposits. It offers a suite of online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, as well as automated teller machines, and banking by telephone, mail and personal appointment. The company's primary sources of revenue are derived from interest and dividends earned on loans, debt and equity securities and other financial instruments.